Health Trials

Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program

ConditionAneurysmal Subarachnoid Hemorrhage
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXiaolin Chen, MD

About this trial

Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood.

This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.

Eligibility criteria

Qualifiers

Adult patients aged ≥18 years;

Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA;

Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization;

Time from onset to aneurysm treatment ≤ 72 hours;

Disqualifiers

History of previous intracranial aneurysm surgery or embolization;

Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage;

Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression;

Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Xiaolin Chen, MD

Lead sponsor

Beijing Tiantan Hospital

Sponsor institution

Peking Union Medical College

Collaborator

Source ClinicalTrials.gov